Daily Ards Research Analysis
Top ARDS-related advances today include: a multicenter prognostic model predicting early intubation after 24 hours of awake prone positioning in COVID-19 hypoxemic failure; preclinical evidence that intranasal delivery of a humanized anti-H7 influenza antibody confers broad, superior protection versus systemic dosing; and neutrophil transcriptomic signatures that align with ventilator weaning trajectories in COVID-19 ARDS.
Summary
Top ARDS-related advances today include: a multicenter prognostic model predicting early intubation after 24 hours of awake prone positioning in COVID-19 hypoxemic failure; preclinical evidence that intranasal delivery of a humanized anti-H7 influenza antibody confers broad, superior protection versus systemic dosing; and neutrophil transcriptomic signatures that align with ventilator weaning trajectories in COVID-19 ARDS.
Research Themes
- Early intubation risk prediction during noninvasive management
- Airway-delivered antibody therapeutics for zoonotic influenza (H7) with ARDS relevance
- Neutrophil transcriptomics as prognostic biomarkers in ARDS
Selected Articles
1. A predictive model for early intubation in patients with COVID-19-induced acute hypoxemic respiratory failure under awake prone position.
In a prospective multicenter cohort of 400 APP-treated COVID-19 ARF patients, 34% required intubation within 72 hours. A 24-hour model using age, respiratory rate, PaO2, FiO2, and SaO2/FiO2 produced a nomogram to estimate early intubation risk, aiming to guide timely escalation of care.
Impact: Provides a pragmatic, physiologically anchored tool for early triage and escalation decisions during noninvasive management of hypoxemic COVID-19.
Clinical Implications: Clinicians can monitor 24-hour response to APP and HFNO and use the nomogram to identify high-risk patients for timely intubation or adjunctive interventions.
Key Findings
- 34% (136/400) required intubation within 72 hours of APP initiation.
- Older age, lower PaO2 and PaO2/FiO2, and higher respiratory rate at baseline and 24 hours were associated with intubation.
- Final 24-hour model variables: age, respiratory rate, PaO2, FiO2, and SaO2/FiO2; a nomogram was developed for individualized risk estimation.
Methodological Strengths
- Prospective multicenter cohort with standardized physiologic data at baseline and 24 hours
- Multivariable modeling with clinically interpretable predictors and nomogram output
Limitations
- No external validation; performance in other populations unknown
- Study period limited to early COVID-19 waves in Argentina; generalizability may be constrained
Future Directions: External validation across diverse settings and integration with dynamic monitoring (e.g., ROX index) to optimize escalation thresholds.
BACKGROUND: Awake prone positioning (APP) reduces the risk of endotracheal intubation and mortality in COVID-19-related acute respiratory failure (ARF) receiving high-flow nasal oxygen (HFNO). However, a significant proportion of patients undergoing APP are ultimately intubated, and mortality in this subgroup remains high. We aimed to develop a predictive model to be applied within the first 24 h of APP to identify patients at higher risk of progressing to intubation within 72 h of APP initiation. METHODS: We conducted a secondary analysis of a prospective multicenter cohort including adult patients with COVID-19-related ARF admitted to six intensive care units in Argentina between June 2020 and January 2021. Eligible patients received HFNO and APP for at least 6 h per day. Physiological variables were collected at ICU admission (baseline) and 24 h after APP initiation. Two multivariable logistic regression models were developed using baseline and 24-hour variables, respectively. Predictors were selected based on clinical relevance and univariable associations. A final model was constructed by integrating variables retained from both time points. RESULTS: Of 400 patients included, 136 (34%) required intubation within the first 72 h. Patients who required intubation were older, had lower PaO₂ and PaO₂/FiO₂ ratios, and higher respiratory rates both at baseline and after 24 h. The final predictive model included five variables: age, respiratory rate, PaO₂, FiO₂, and SaO₂/FiO₂ ratio, all measured 24 h after APP initiation. A nomogram was developed based on this model to estimate the individual risk of early intubation. CONCLUSION: In patients with COVID-19-related ARF treated with HFNO and APP, a model combining baseline characteristics and early physiological response can help predict the need for intubation within 72 h. This tool may support clinicians in identifying high-risk patients and making timely, individualized decisions about escalation of care.
2. Direct airway delivery of a humanized anti-H7N9 neutralizing antibody broadly protects against divergent H7 influenza viruses in the mouse model.
In mice, intranasal delivery of a humanized anti-H7N9 antibody (chi4B7) provided broad prophylactic and therapeutic protection against diverse H7 influenza strains, outperforming intraperitoneal dosing and reducing required prophylactic doses. Epitope targeting in hemagglutinin and sustained cross-reactivity support airway-delivered antibodies as a potent strategy.
Impact: Demonstrates route-of-delivery–dependent superiority of airway-delivered mAbs against zoonotic influenza with ARDS relevance, informing translational design of respiratory antibody therapies.
Clinical Implications: Supports development of inhaled/intranasal antibody therapies for severe zoonotic influenza, potentially enabling earlier outpatient prophylaxis and targeted lung delivery to mitigate ARDS progression.
Key Findings
- Intranasal antibody administration reduced the dose needed for prophylactic protection against H7N9 versus systemic (intraperitoneal) dosing.
- Airway-delivered chi4B7 conferred broad prophylactic and therapeutic protection across divergent H7 strains in mice.
- The antibody targeted critical residues in H7 hemagglutinin and maintained cross-H7 binding, hemagglutination inhibition, and neutralization.
Methodological Strengths
- Direct comparison of airway versus systemic administration with in vivo efficacy readouts
- Humanization of the mAb with preservation of cross-reactivity and functional activity
Limitations
- Mouse model may not fully recapitulate human pharmacokinetics and safety
- Focused on H7 subtype; generalizability to other zoonotic subtypes remains to be shown
Future Directions: Evaluate dosing, durability, and safety in large animals and early-phase human studies; optimize formulations/devices for intranasal delivery.
Passive administration of broadly neutralizing anti-influenza monoclonal antibodies (mAbs) before or after virus infection can prevent or alleviate disease. Unlike seasonal influenza, infection with zoonotic avian influenza viruses can lead to acute respiratory distress syndrome and high mortality in humans. Respiratory tract-targeting antibody delivery appears to be more clinically relevant and effective for zoonotic influenza treatment. In this study, the efficacy of an anti-H7N9 murine mAb 4B7 and its humanized form (chi4B7) against H7 subtype influenza viruses administered through the intranasal route was investigated in mice. 4B7 recognizes critical residues in the vestigial esterase domain and receptor-binding sites in the hemagglutinin of H7N9 virus. The antibody had cross-H7 binding, hemagglutination inhibition, and neutralizing activities. In particular, the dose of 4B7 required for prophylactic protection against H7N9 infection was significantly reduced in mice treated locally (intranasal) compared with those treated systemically (intraperitoneal). Intranasal delivery of the antibody also enhanced therapeutic efficacy against H7N9 infection compared to intraperitoneal administration. Chi4B7 generated by grafting the variable regions onto the human IgG1 backbone sustained cross-reactivity with different H7 viruses of the parental murine antibody. Airway-delivered chi4B7 provided broad prophylactic and therapeutic protection against divergent H7 viruses in mice. Moreover, intranasal administration of chi4B7 had a long effective prophylaxis window against H7N9 infection. Our results suggest that airway delivery of the humanized anti-H7 antibody is a favorable approach for broad-spectrum prophylaxis and therapy against the H7 subtype influenza.IMPORTANCEInfection of zoonotic H7 avian influenza viruses can cause severe respiratory symptoms and high mortality in humans. Monoclonal antibody administration is an effective approach for treatment of zoonotic influenza infection, while systematic routes of antibody administration (typically intravenous infusion) have several shortcomings. However, there are no approved anti-H7 antibody therapies, and the efficacy of antibodies administered through the airway route against H7 viruses has not been fully investigated. Herein, we report a murine broadly neutralizing monoclonal antibody against divergent H7 viruses and reveal that intranasal administration enhanced prophylactic and therapeutic efficacy of this antibody against H7N9 virus compared to systemic administration. Airway delivery of the humanized antibody conferred broad protection against diverse strains of H7 virus in mice. Our study presents new candidates of broad antiviral agents against H7 avian influenza viruses and highlights airway delivery as a more potent manner of administering antibodies for clinical treatment of influenza.
3. Neutrophil gene expression in COVID-19 patients with acute respiratory distress syndrome.
Bulk RNA-seq showed heightened neutrophil-associated gene expression in COVID-19 ARDS versus healthy controls. Single-cell RNA-seq of a separate cohort stratified patients into ventilator-weaning versus non-weaning groups at 28 days, suggesting transcriptomic signatures may relate to clinical trajectories.
Impact: Links neutrophil transcriptomic programs with ventilator-weaning outcomes, advancing biomarker discovery for ARDS stratification.
Clinical Implications: Neutrophil gene-expression profiles could inform early risk stratification and targeted immunomodulation strategies in COVID-19 ARDS.
Key Findings
- Bulk RNA-seq: COVID-19 ARDS patients exhibited elevated neutrophil-associated gene expression versus healthy controls.
- Clinical clustering did not differentiate ARDS subgroups, but single-cell RNA-seq stratified patients by 28-day ventilator weaning status.
- Single-cell analysis identified neutrophil subpopulation differences aligned with weaning trajectories.
Methodological Strengths
- Integration of bulk and single-cell RNA-seq to interrogate neutrophil biology
- Use of clinical outcome (28-day ventilator weaning) to anchor transcriptomic clusters
Limitations
- Small sample sizes, especially for single-cell cohort (n=5)
- Observational design limits causal inference; external validation needed
Future Directions: Validate neutrophil transcriptomic signatures in larger, multi-center ARDS cohorts and test links to response to immunomodulators.
BACKGROUND: Although an increase in neutrophil count has been observed in patients with coronavirus disease 2019 (COVID-19), the relationship between the systemic neutrophil transcriptome and clinical course of COVID-19 remains unclear. Hence, we examined the relationship between the clinical course and RNA sequencing analysis results in COVID-19 patients. METHODS: Peripheral blood samples were obtained from 28 patients with COVID-19-associated ARDS and 16 healthy controls. Bulk RNA sequencing was performed, and clustering analysis was used to explore relationships between gene expression and clinical characteristics. In a separate cohort, neutrophils were isolated from the peripheral blood of five COVID-19 patients with ARDS for single-cell RNA sequencing to further characterize the neutrophil subpopulations. RESULTS: In bulk RNA sequencing analysis, COVID-19 patients with ARDS had elevated gene expression associated with neutrophils compared with healthy controls.Clustering analysis revealed no differences in the clinical characteristics of COVID-19 patients with ARDS. In the single-cell RNA sequencing analysis, clustering analysis showed that the patients were divided into two groups: those who could be weaned from the ventilator within 28 days and those who could not be weaned. CONCLUSION: These findings indicate that differences in neutrophil gene expression may have important clinical implications. This study may support the exploratory identification of genomic factors, such as neutrophil gene expression, that are relevant to clinical parameters.